Scholarlink

<p>Elexacaftor/Tezacaftor/Ivacaftor (ETI) has led to major pulmonary and nutritional benefits in youth with cystic fibrosis (YwCF), but its effects on physical activity (PA) and health-related quality of life (HRQoL) remain unclear. This study investigated changes in PA and HRQoL according to modulator trajectory (ETI-naïve, ETI-initiated, ETI-throughout). YwCF aged 6–17 years completed assessments at baseline and follow-up (12–18 months). PA was measured using ActiGraph GT3X + BT accelerometers over seven days. Time in moderate-to-vigorous PA (MVPA) and total PA were converted to sex- and age-specific z-scores calculated from a healthy reference cohort (<i>n</i> = 264). HRQoL was evaluated using the Cystic Fibrosis Questionnaire. Thirty-four YwCF (38% male; 13.1 ± 3.8 years) were included. Changes in MVPA (<i>p</i> = 0.74) and total PA (<i>p</i> = 0.73) did not differ across modulator trajectories. MVPA z-scores increased numerically in all groups, while total PA z-scores remained stable. YwCF who initiated or already received ETI reported lower treatment burden and fewer respiratory symptoms, whereas changes in physical functioning varied.ETI did not lead to additional improvements in PA, although improvements were observed in some HRQoL domains. Larger longitudinal studies are required to clarify mechanisms underlying PA and HRQoL in the modulator era.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

One year follow-up of physical activity and health-related quality of life in youth with Cystic Fibrosis in the modulator era

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月27日

查看全文
  • Manon Kinaupenne,
  • Ines Vandekerckhove,
  • Stephanie Van Biervliet,
  • Heidi Schaballie,
  • Kristof Vandekerckhove,
  • Heleen Demeyer,
  • Marieke De Craemer

摘要

Elexacaftor/Tezacaftor/Ivacaftor (ETI) has led to major pulmonary and nutritional benefits in youth with cystic fibrosis (YwCF), but its effects on physical activity (PA) and health-related quality of life (HRQoL) remain unclear. This study investigated changes in PA and HRQoL according to modulator trajectory (ETI-naïve, ETI-initiated, ETI-throughout). YwCF aged 6–17 years completed assessments at baseline and follow-up (12–18 months). PA was measured using ActiGraph GT3X + BT accelerometers over seven days. Time in moderate-to-vigorous PA (MVPA) and total PA were converted to sex- and age-specific z-scores calculated from a healthy reference cohort (n = 264). HRQoL was evaluated using the Cystic Fibrosis Questionnaire. Thirty-four YwCF (38% male; 13.1 ± 3.8 years) were included. Changes in MVPA (p = 0.74) and total PA (p = 0.73) did not differ across modulator trajectories. MVPA z-scores increased numerically in all groups, while total PA z-scores remained stable. YwCF who initiated or already received ETI reported lower treatment burden and fewer respiratory symptoms, whereas changes in physical functioning varied.ETI did not lead to additional improvements in PA, although improvements were observed in some HRQoL domains. Larger longitudinal studies are required to clarify mechanisms underlying PA and HRQoL in the modulator era.